Showing results for:
Acalabrutinib is a kinase inhibitor indicated:In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).For the treatment of adult patients with MCL who have received at least one prior therapy.For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Calquence® Acalabrutinib
Alemtuzumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL).
Campath® Alemtuzumab
Calaspargase pegol-mknl is FDA approved as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
Asparlas® Calaspargase pegol-mknl
Carboplatin is FDA approved to treat people who have certain kinds of cancer, including some blood cancers. Carboplatin may cause temporary loss of hair during treatment. Normal hair growth should return after treatment ends.
Paraplatin® Carboplatin
Carfilzomib is indicated in combination withLenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. It is also indicated as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.In a clinical study of relapsed multiple myeloma, carfilzomib and dexamethasone kept the disease from getting worse longer than bortezomib and dexamethasone (median of 18.7 months compared with 9.4 months) and helped patients live longer (median of 47.6 months compared with 40 months).Daratumumab (Darzalex®) plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy.
Kyprolis® Carfilzomib
Carmustine is FDA approved to treat people who have myeloma (in combination with prednisone); relapsed or refractory Hodgkin lymphoma (as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy or who fail to respond to primary therapy); relapsed or refractory non-Hodgkin lymphoma (as secondary therapy in combination with other approved drugs).
BiCNU® BCNU Carmustine
Chlorambucil is FDA approved to treat people who have chronic lymphocytic leukemia (CLL), some types of non-Hodgkin lymphoma and advanced Hodgkin lymphoma.
Leukeran® Chlorambucil
Ciltacabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Carvykti™ Ciltacabtagene autoleucel
Cisplatin is FDA approved alone or in combination with other drugs to treat people who have certain types of cancer.
Platinol®-AQ Cisplatin
Cladribine is FDA approved to treat people who have active hairy cell leukemia. It is also used to treat some other types of leukemia and lymphoma.
Leustatin® 2-CdA Cladribine
Clofarabine is FDA approved to treat children and young adults (1- 21 years old) with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.
Clolar® Clofarabine
Cobimetinib is indicated as a single agent for the treatment of adult patients with histiocytic neoplasms.
Cobimetinib Cotellic®
Copanlisib is FDA approved for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Aliqopa® Copanlisib
Crizotinib is FDA approved for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.Limitations of Use: The safety and efficacy of Xalkori have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.
Xalkori® Crizotinib
Cyclophosphamide is FDA approved to treat several types of cancer, including people who have Hodgkin lymphoma, non-Hodgkin lymphoma, acute and chronic lymphocytic leukemia, acute and chronic myeloid leukemia, myeloma, and mycosis fungoides. Cyclophosphamide is usually used in combination with other drugs.Cyclophosphamide may cause a temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although the new hair may be a slightly different color or texture.
Cytoxan® Cyclophosphamide
Cytarabine is FDA approved to prevent and treat leukemia that has spread to the meninges (the three membranes that cover the brain and spinal cord). It is also FDA approved for use with other drugs to treat acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid leukemia. This medicine may cause a temporary loss of hair in some people. After treatment with cytarabine has ended, normal hair growth should return.Liposomal cytarabine (DepoCyt®) is given by intrathecal injection. It is FDA approved to treat lymphoma that has spread to the meninges.
Cytosar-U® Cytosine arabinoside Ara-C Cytarabine Liposomal cytarabine DepoCyt®
Daunorubicin is FDA approved for use in combination with other approved anticancer drugs for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphoblastic leukemia of children and adults. Daunorubicin causes urine to turn reddish in color, which may stain clothes. This is not blood. It is perfectly normal and lasts for only 1 or 2 days after each dose is given. This medicine often causes a temporary and total loss of hair. After treatment with daunorubicin has ended, normal hair growth should return.
Cerubidine® Daunorubicin
Glofitamab-gxbm is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.
Glofitamab-gxbm Columvi™
Lomustine is FDA approved as a secondary therapy in combination with other drugs to treat people with Hodgkin lymphoma who relapse while being treated with primary therapy or who fail to respond to primary therapy.
CeeNU® CCNU Lomustine